Genmab A/S
CSE:GMAB
Genmab A/S
Additional Paid In Capital
Genmab A/S
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
Additional Paid In Capital
kr12.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
6%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Additional Paid In Capital
kr14.7B
|
CAGR 3-Years
51%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Saniona AB
STO:SANION
|
Additional Paid In Capital
kr884.7m
|
CAGR 3-Years
3%
|
CAGR 5-Years
30%
|
CAGR 10-Years
48%
|
|
Genmab A/S
Glance View
In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.
See Also
What is Genmab A/S's Additional Paid In Capital?
Additional Paid In Capital
12.6B
DKK
Based on the financial report for Dec 31, 2024, Genmab A/S's Additional Paid In Capital amounts to 12.6B DKK.
What is Genmab A/S's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
6%
Over the last year, the Additional Paid In Capital growth was 1%. The average annual Additional Paid In Capital growth rates for Genmab A/S have been 2% over the past three years , 1% over the past five years , and 6% over the past ten years .
You don't have any saved screeners yet